Zacks Investment Research Lowers Inventiva (NYSE:IVA) to Hold

Inventiva (NYSE:IVAGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, “Inventiva S.A. is a clinical-stage biopharmaceutical company. It is focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. Inventiva S.A. is based in Daix, France. “

Shares of NYSE:IVA opened at $8.85 on Tuesday. Inventiva has a 52 week low of $8.00 and a 52 week high of $16.93. The company’s 50 day moving average is $10.53 and its two-hundred day moving average is $12.25.

Several large investors have recently made changes to their positions in the business. Credit Suisse AG grew its position in shares of Inventiva by 6.4% in the 3rd quarter. Credit Suisse AG now owns 35,860 shares of the company’s stock valued at $507,000 after buying an additional 2,148 shares during the last quarter. NEA Management Company LLC grew its position in shares of Inventiva by 24.7% in the 3rd quarter. NEA Management Company LLC now owns 1,298,700 shares of the company’s stock valued at $18,390,000 after buying an additional 257,034 shares during the last quarter. Finally, BVF Inc. IL grew its position in shares of Inventiva by 408.9% in the 3rd quarter. BVF Inc. IL now owns 544,500 shares of the company’s stock valued at $7,705,000 after buying an additional 437,500 shares during the last quarter.

Inventiva Company Profile (Get Rating)

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH.

Read More

Get a free copy of the Zacks research report on Inventiva (IVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.